Synonyms that are in the dictionary are marked in green. Synonyms that are not in the dictionary are marked in red.
Antonyms that are in the dictionary are marked in green. Antonyms that are not in the dictionary are marked in red.
ARK Investment Management also increased its exposure to companies including Block (), Verve Therapeutics (), Intellia Therapeutics (
Cantor Fitzgerald restated an “overweight” rating and set a $65.00 price target on shares of Intellia Therapeutics in a report on Tuesday, August 29th.
Citigroup Inc. trimmed its stake in Intellia Therapeutics, Inc. () by 15.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission.
Finally, Arizona State Retirement System boosted its position in Intellia Therapeutics by 4.0% during the fourth quarter.
Finally, Chardan Capital reduced their price objective on shares of Intellia Therapeutics from $111.00 to $107.00 in a research note on Tuesday, June 13th.
Intellia Therapeutics ( genome editing company, striving to develop curative therapies using CRISPR-based technologies.
Intellia Therapeutics’s revenue for the quarter was down 3.1% on a year-over-year basis.
On average, sell-side analysts forecast that Intellia Therapeutics, Inc. will post -5.64 EPS for the current fiscal year.